The widespread use of medical cannabis and the following natural rush have sparked a growing interest in identifying and isolating cannabinoids that are thought to have healing potential.
The cannabis industry is frantically looking for other cannabinoids to link the newly released cannabinoids, which are often mistakenly regarded as the “medical” counterpart to the buzz-inducing tetrahydrocannabidiol ( THC).
The search is on for” the next CBD”, and industry pioneers like GW Pharmaceuticals appear to have set their sights on cannabigerol ( CBG), a much lesser-known cannabinoid, but one necessary for the production of the plant’s more famous ingredients: as the” stem cell” of cannabis, CBG is the first cannabinoid present in the plant and is converted into THC, CBD, and other cannabinoids by the time of harvest.
The majority of research into cannabis has focused on its transitional properties as a key component in understanding how the plant developed, but its significance to the plant’s development has sparked a rise of attention in its own potential health properties.
CBG has been linked to care of a much number of ailments— including glaucoma, cancers, Huntington’s Disease, pain and nausea — and the industry is talking about the compound’s possible. CBG has equivalent benefits to CBD, but acts on various neurons.
CBG research is still in its early stages, with only preclinical trials and animal studies that provide more proposals than conclusions.
Paul Armentano, deputy chairman of NORML, said scientific studies in CBG is growing.
” Despite CBG being isolated in 1964, there are comparatively few peer-reviewed analyses of its potential therapeutic parameters”, he said. ” With that said, there seems to be renewed interest among scientists regarding non-THC cannabinoids and their potential medical applications, so my supposition is that we will begin to see more emphasis on CBG and other non-euphoric inducing phytocannabinoids ( cannabinoids that originate from plants )”,” he said.
Due to the cold impact of prohibition on money and the trend for research to concentrate on extracted cannabinoids rather than their social effects, studying the cannabis grow is a challenging endeavor.
Researchers at the University of California are pointing to an “entourage impact” that involves a combination of several thc acting up on various receptor in the head, just as nutritionists have emphasized the value of whole-plant foods.
Artist of” Smoke Signals: A Social History of Marijuana — Medical, Recreational and Scientific” and chairman of Project CBD, Martin Lee, expects CBG to become an essential cannabinoid in health products, but stressed the importance of whole-plant treatments over isolated cbd.
” Given the fact that cannabinoids in general have precious therapeutic properties, there is no reason to think it would n’t be the case for CBG, particularly because it is the formative cannabinoid”, he said. It makes perfect sense that it would be quite remarkable to those who observe it.
But Lee raised an essential disclaimer.
” These tests are based on individual molecule CBG and that’s unique from the grow”, he said. CBG may contribute to the plant’s “entourage result.” If it looks great as a second protein, imagine how it would be a part of CBG-rich grow”.
Actually published in Matter 26 of Cannabis Today. LEARN Less
TELL US, have you tried CBG?
